Cover Image
市場調查報告書

重症肌無力 (MG) :主要26個市場預測

Epiomic Epidemiology Series: Myasthemia Gravis Forecast in 26 Major Markets 2017-2027

出版商 Black Swan Analysis 商品編碼 486816
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
重症肌無力 (MG) :主要26個市場預測 Epiomic Epidemiology Series: Myasthemia Gravis Forecast in 26 Major Markets 2017-2027
出版日期: 2017年04月01日 內容資訊: 英文 92 Pages
簡介

本報告提供主要13個市場 (美國、加拿大、法國、德國、義大利、西班牙、英國、愛爾蘭、丹麥、荷蘭、挪威、瑞典、愛沙尼亞、克羅埃西亞、波蘭俄羅斯、希臘、土耳其、日本、中國、韓國、阿根廷、巴西、墨西哥、印度、澳洲) 的重症肌無力 (MG)的目前患者數 (性別,年齡世代) 調查分析,目前盛行率,加上疾病概要,危險因素,與疾病診斷預後,主要的症狀和併發症等系統性資訊。

圖表

簡介

病因

危險因素和預防

疾病診斷

變異:各地區/民族

疾病預後和臨床過程

疾病相關的主要併發症/特徵

患者數的定量化方法

MG的最大患病人數

MG患者的分類

  • MG的自我抗體的血清型/存在
  • MG患者的合併症與症狀

簡稱

相關出版

病患人數的線上資料庫

病患人數的產品

線上價格資料、平台

參考文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MSGV0010417

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Myasthenia Gravis in 26 Major Markets

Myasthenia Gravis (MG), also known as autoimmune myasthenia, is one of the most significant diseases affecting the neuromuscular junction. The disorder is caused by auto-antibodies that target components of the post-synaptic muscle endplate. This includes antibodies that target acetylcholine receptors (AChR), muscle-specific kinase (MUSK) and lipoprotein release protein 4 (LRP4). Please note that this module does not cover congenital MG forms.

This report provides the current prevalent population for Myasthenia Gravis across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Ireland, Denmark, Netherlands, Norway, Sweden, Estonia, Croatia, Poland, Russia, Greece, Turkey, Japan, China, South Korea, Argentina, Brazil, Mexico, India and Australia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Myasthenia Gravis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

MG often co-occurs with other autoimmune conditions including:

  • RA
  • MS
  • Ankylosing spondylitis
  • Psoriasis
  • Sjogren's syndrome
  • Ulcerative colitis
  • Crohn's disease
  • Other forms of AI

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Myasthenia Gravis market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Myasthenia Gravis and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Myasthenia Gravis prevalent population.
  • Identify sub-populations within Myasthenia Gravis which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Myasthenia Gravis patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Comorbid Conditions/Features Associated with the Disease
  • Methodology for quantification of patient numbers
  • Top-line Prevalence for Myasthenia Gravis
  • Classification of Myasthenia Gravis Patients
    • Serotype/Presence of Autoantibodies in Myasthenia Gravis
    • Comorbidities and Symptoms of Myasthenia Gravis patients
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Figures

  • MG at the neuromuscular junction

List of Tables

  • Osserman criteria for severity staging of Myasthenia Gravis
  • Myasthenia Gravis Foundation of America criteria for severity staging
  • Prevalence of MG,total (000s)
  • Prevalence of MG, males (000s)
  • Prevalence of MG, females (000s)
  • MG patients by phenotype, total (000s)
  • MG patients by subtype, total (000s)
  • MG patients by severity, total (000s)
  • AChR seropositive MG, total (000s)
  • MUSK seropositive MG, total (000s)
  • LRP4 seropositive MG, total (000s)
  • MG patients with Thymoma, total (000s)
  • MG patients in Crisis, total (000s)
  • MG patients with Ptosis, total (000s)
  • MG patients with Dysphagia, total (000s)
  • MG patients with diplopia, total (000s)
  • MG patients with another autoimmune condition, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • USA Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Canada Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Canada Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • France Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • France Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Germany Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Germany Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Italy Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Italy Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Spain Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Spain Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • UK Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • UK Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Ireland Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Ireland Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Denmark Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Denmark Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Netherlands Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Norway Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Norway Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Sweden Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Sweden Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Estonia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Estonia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Croatia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Croatia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Poland Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Poland Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Greece Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Greece Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Turkey Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Turkey Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Argentina Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Argentina Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Mexico Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Mexico Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Japan Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Japan Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • South Korea Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • South Korea Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • India Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • India Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Australia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Australia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • China Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • China Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
  • Russia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
  • Russia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Back to Top